Hyperprolactinemia and insulin resistance.
Gierach M, Bruska-Sikorska M, Rojek M, Junik R.
Endokrynol Pol. 2022;73(6):959-967. doi: 10.5603/EP.a2022.0075.
Prolactin-secreting adenomas: pathogenesis, diagnosis, and management.
Fleseriu M, Varlamov EV, Akirov A, Langlois F, Petersenn S, Melmed S.
Lancet Diabetes Endocrinol. 2025 Oct;13(10):874-890. doi: 10.1016/S2213-8587(25)00227-X. Epub 2025 Aug 25.
Metabolic effects of prolactin.
Pirchio R, Graziadio C, Colao A, Pivonello R, Auriemma RS.
Front Endocrinol (Lausanne). 2022 Sep 27;13:1015520. doi: 10.3389/fendo.2022.1015520. eCollection 2022.
[Hyperprolactinemia and prolactinemia--investigation and treatment].
Svartberg J, Carlsen SM, Cappelen J, Aanderud S, Johansen ML, Schreiner T, Kollevold T, Bakke S, Bollerslev J.
Tidsskr Nor Laegeforen. 2002 Feb 20;122(5):494-8.
Vitex agnus-castus extracts for female reproductive disorders: a systematic review of clinical trials.
van Die MD, Burger HG, Teede HJ, Bone KM.
Planta Med. 2013 May;79(7):562-75. doi: 10.1055/s-0032-1327831. Epub 2012 Nov 7.
Hyperprolactinemia in children and adolescents and longterm follow-up results of prolactinoma cases: a single-centre experience.
Kontbay T, Şıklar Z, Özsu E, Uyanık R, Bilici E, Ceran A, Berberoğlu M.
Turk J Pediatr. 2022;64(5):892-899. doi: 10.24953/turkjped.2021.4639.
[Physiopathological link between polycystic ovary syndrome and hyperprolactinemia: myth or reality?].
Robin G, Catteau-Jonard S, Young J, Dewailly D.
Gynecol Obstet Fertil. 2011 Mar;39(3):141-5. doi: 10.1016/j.gyobfe.2010.11.002.
Hyperprolactinaemia.
Patel SS, Bamigboye V.
J Obstet Gynaecol. 2007 Jul;27(5):455-9. doi: 10.1080/01443610701406125.
[Hyperprolactinemia in systemic lupus erythematosus. A prospective study of 38 cases].
Smiti Khanfir M, Ben Ghorbel I, Feki M, Lamloum M, Mebazaa A, Miled M, Houman MH.
Tunis Med. 2004 Jun;82(6):512-5.
Hyperprolactinaemia.
Prabhakar VK, Davis JR.
Best Pract Res Clin Obstet Gynaecol. 2008 Apr;22(2):341-53. doi: 10.1016/j.bpobgyn.2007.08.002. Epub 2007 Sep 21.
